2 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
Follow entrectinib: new trials by email Literature Review of entrectinib trials Research Report on entrectinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) Entrectinib, Letrozole, Goserelin - Invasive Lobular Breast Carcinoma, ER+ Breast Cancer | Phase 2 | Unknown | Jules Bordet Institute | 65 | 2021-01-14 | 2024-12-04 |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer | Phase 2 | Unknown | Fondazione per la Medicina Personalizzata | 400 | 2020-10-07 | 2023-10-03 |
Breast Neoplasms (1) · Carcinoma, Lobular (1) · Carcinoma, Non-Small-Cell Lung (1) · Gastrointestinal Neoplasms (1)
Fondazione per la Medicina Personalizzata (1) · Jules Bordet Institute (1)
Belgium (1) · France (1) · Italy (1)
Andrea Botticelli (1) · Paolo Marchetti (1) · Philippe Aftimos, MD (1)
PMID 35119530, PMID 35695563, PMID 41023484, PMID 41963505
2018 (1)